Semaglutide Dose Schedule: Full Titration Guide

Semaglutide requires graduated dose increases. Starting at the full therapeutic dose would cause severe side effects in most patients. The titration schedule is not arbitrary – it reflects clinical trial data showing which escalation pattern balances tolerability with reaching therapeutic effect efficiently. This post covers the standard semaglutide dose schedule for weight loss and diabetes, when and how to adjust the schedule, and what to expect at each dose level.

Standard Wegovy Dose Schedule for Weight Loss

The FDA-approved titration schedule for Wegovy (semaglutide for chronic weight management):

Weeks 1-4: 0.25 mg once weekly

Weeks 5-8: 0.5 mg once weekly

Weeks 9-12: 1.0 mg once weekly

Weeks 13-16: 1.7 mg once weekly

Week 17 and onward: 2.4 mg once weekly (maintenance)

This represents the recommended fastest escalation. Each dose level is maintained for 4 weeks before moving up. The full protocol reaches maintenance dose at week 17.

The FDA prescribing information for Wegovy specifies this titration schedule and emphasizes that failure to follow it increases the risk of gastrointestinal side effects.

Standard Ozempic Dose Schedule for Diabetes

The FDA-approved titration schedule for Ozempic (semaglutide for type 2 diabetes):

Weeks 1-4: 0.25 mg once weekly (starter dose, no clinical effect expected)

Weeks 5-8: 0.5 mg once weekly

Weeks 9-12: 1.0 mg once weekly (or stay at 0.5 mg if this is effective)

Week 13 and onward: 2.0 mg once weekly (maximum dose if needed for glucose control)

Note that Ozempic has no 1.7 mg step and a maximum dose of 2.0 mg (vs Wegovy’s 2.4 mg). The FDA prescribing information for Ozempic allows clinicians to hold at intermediate doses if glucose control is adequate, without needing to push to maximum.

Why the Titration Exists

Gastrointestinal side effects are dose-dependent. A patient started at 2.4 mg from day one would have severe nausea, vomiting, and potentially dangerous dehydration. Clinical trials demonstrated that:

• 0.25 mg starting dose produces mild side effects most patients tolerate
• Each dose level increase produces a modest side effect wave that typically settles within 1-2 weeks
• Patients who reach 2.4 mg via gradual titration usually tolerate it well
• Patients who try to jump steps or escalate faster have much higher dropout rates

The titration is essentially a built-in adaptation period at each level. Your body acclimates to the GLP-1 receptor activation at one level before being pushed higher.

When to Slow Down the Titration

The 4-week schedule is the fastest safe pace. Many patients benefit from a slower pace. Consider extending time at each dose level when:

• Significant nausea or vomiting persists beyond 10-14 days at the current dose
• Weight loss is progressing well at the current dose (no urgency to escalate)
• Side effects require medication to manage
• Hydration is becoming difficult due to GI symptoms
• Work or life circumstances make managing side effects harder right now

Slowing titration is a clinical decision made with your provider. Options include staying at the current dose for an additional 2-4 weeks, or moving to an intermediate dose if compounded products are available.

Some patients do best at 8-week intervals between dose changes rather than 4. This extended pace still reaches maintenance, just over 28-32 weeks instead of 16.

When You Might Not Need Maximum Dose

Many patients achieve their goals at intermediate doses without needing to reach 2.4 mg. Staying at a lower dose is appropriate when:

• Weight loss is progressing at 1 to 2 pounds per week at 1.0 or 1.7 mg
• Appetite suppression is adequate at the current level
• Side effects are significantly worse at higher doses
• You are nearing or at your target weight
• Cost or insurance considerations favor the lower dose

There is no clinical mandate to reach maximum dose. The goal is the lowest effective dose that produces your desired outcome. Roughly 30 to 40 percent of patients do well long-term at 1.0 or 1.7 mg rather than needing 2.4 mg.

When Faster Titration Might Be Appropriate

Occasionally a patient moves through titration faster than the standard schedule. This is less common and should only be done with clinical judgment:

• Patients who have previously tolerated high-dose GLP-1 medications without issue
• Patients returning to semaglutide after a brief break
• Patients with minimal response at starting doses who are escalating quickly to reach effective levels

Faster titration risks more severe side effects. The standard 4-week schedule is the default for a reason.

Managing Side Effects at Each Dose Level

Each new dose level may bring a wave of side effects that typically peaks in the first week and settles over 2-4 weeks.

0.25 mg (weeks 1-4): Initial adaptation period. Mild to moderate nausea common. Usually manageable with food choices and hydration.

0.5 mg (weeks 5-8): Second wave of nausea possible but usually milder. Appetite changes become more noticeable.

1.0 mg (weeks 9-12): Often the dose where effects become clearly therapeutic. Side effects usually tolerable.

1.7 mg (weeks 13-16): Wegovy-specific step. Some patients have notable side effect resurgence here.

2.4 mg (week 17+): Maximum dose. Some patients have difficulty with this level; others tolerate it well.

What to Do if You Miss a Dose Change

Life happens. Sometimes the scheduled dose change is missed. Guidelines:

If you forget to move up: Stay at the current dose for another week, then escalate at your next scheduled injection.

If you missed a recent injection entirely: See our missed dose protocol for specific guidance. Generally, injections more than 5 days late require contacting your provider.

If you need to pause for illness or surgery: Your provider may advise pausing and potentially restarting at a lower dose depending on how long you have been off.

Alternative Schedules Sometimes Used

Some clinicians use non-standard titration schedules for specific reasons:

Compound-specific intermediate doses. Compounded semaglutide allows doses between the standard steps (0.375, 0.75, 1.25, 2.0 mg, etc). Some patients titrate through these smaller steps for better tolerance.

Extended titration. 6 or 8 weeks at each dose level instead of 4. Often used for patients with significant side effect sensitivity.

Pause and resume. Staying at an effective dose without further escalation, then escalating only if progress plateaus.

Reverse titration for discontinuation. When stopping semaglutide, stepping down gradually through lower doses rather than abrupt discontinuation. Helpful for smoother transition.

These variations should be implemented with your prescribing clinician, not self-directed. A good provider tailors the titration to your specific response pattern.

Tracking Your Progress Through Titration

Useful information to track during titration:

• Date and dose of each injection
• Weekly weight
• Side effect intensity (1-10 scale) for the first week of each new dose
• Appetite and hunger notes
• Any medications taken for side effect management

This data helps you and your provider make decisions about titration pace, dose adjustments, and when to hold at a given level. Most patients overestimate how bad side effects were in retrospect; written records give accurate perspective.

Dose Adjustments for Special Situations

Some situations warrant modifications to the standard titration:

Kidney impairment. Generally no dose adjustment required, but monitor closely for GI side effects that can affect hydration and kidney function.

Liver impairment. No dose adjustment required for mild to moderate impairment. Severe impairment warrants careful risk-benefit review.

Older adults (65+). No specific dose adjustment, but titration may need to be slower due to higher risk of dehydration and falls from GI symptoms.

Lower body weight patients. May reach effective appetite suppression at 0.5 or 1.0 mg and not need full escalation.

Higher body weight patients. Usually need to reach 2.4 mg for optimal results but do so at the standard pace.

The Honest Summary on Semaglutide Dose Schedule

The standard semaglutide dose schedule is a 16-week titration from 0.25 mg to 2.4 mg at 4-week intervals. The schedule exists to balance reaching therapeutic dose with managing side effects. Your pace may appropriately be slower than the standard if side effects require it. You may not need to reach the maximum dose if a lower dose is producing good results. Work with your prescribing provider to tailor the titration to your specific tolerance and goals. The right dose is the one that works for you with manageable side effects, not automatically the highest available.